• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide.

作者信息

Lormeau J C, Herault J P

机构信息

Sanofi Recherche Centre Choay, Gentilly, France.

出版信息

Thromb Haemost. 1993 Feb 1;69(2):152-6, 176.

PMID:8384381
Abstract

The inhibiting effect of standard heparin, CY216 and the ATIII-binding synthetic pentasaccharide on extrinsic and intrinsic thrombin generation were quantified by evaluating the decrease of the total amount of active thrombin appearing in plasma after triggering coagulation. Heparin as well as CY216 produced the same quantitative inhibition of extrinsic and intrinsic TGs whereas pentasaccharide inhibited more efficiently extrinsic TG. This pattern of inhibition was further confirmed on pure extrinsic or intrinsic coagulation respectively in factor IX- and factor VII-depleted plasmas. Furthermore, selective suppression of the anti-thrombin activity of CY216 by limited amounts of PF4 affected the intrinsic TG inhibition more markedly than the extrinsic one. It was concluded that anticoagulant activity produced mainly through thrombin scavenging leads to similar quantitative impairment of extrinsic and intrinsic coagulation, while selective ATIII-mediated factor Xa inhibition results in a more marked effect against the extrinsic system.

摘要

相似文献

1
Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide.
Thromb Haemost. 1993 Feb 1;69(2):152-6, 176.
2
The action of a synthetic pentasaccharide on thrombin generation in whole plasma.一种合成五糖对全血中凝血酶生成的作用。
Thromb Haemost. 1989 Jun 30;61(3):397-401.
3
Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.新型合成类肝素对大鼠体内外全血凝血酶生成的影响。
Thromb Haemost. 2002 Feb;87(2):238-44.
4
The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.皮下注射普通肝素和低分子量肝素对富血小板血浆中凝血酶生成的影响——一项在人类志愿者中的研究。
Thromb Haemost. 1994 Nov;72(5):705-12.
5
The effect of the synthetic pentasaccharide SR 90107/ORG 31540 on thrombin generation ex vivo is uniquely due to ATIII-mediated neutralization of factor Xa.合成五糖SR 90107/ORG 31540对体外凝血酶生成的影响完全归因于抗凝血酶III(ATIII)介导的对Xa因子的中和作用。
Thromb Haemost. 1995 Dec;74(6):1474-7.
6
Heparin chain-length dependence of factor Xa inhibition by antithrombin in plasma.血浆中抗凝血酶对因子Xa抑制作用的肝素链长依赖性。
Thromb Res. 2007;119(4):481-8. doi: 10.1016/j.thromres.2006.01.009. Epub 2006 Mar 2.
7
Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide-pentasaccharide-docked complexes.通过生物物理和生物学分析以及肽-五糖对接复合物的分子建模评估抗凝血酶III-肝素相互作用的结构-功能关系。
Arch Biochem Biophys. 1996 Oct 15;334(2):206-13. doi: 10.1006/abbi.1996.0448.
8
Mechanism of low-molecular-weight heparin reversal by platelet factor 4.血小板第4因子对低分子量肝素的逆转机制。
Thromb Res. 2009 May;124(1):149-55. doi: 10.1016/j.thromres.2008.12.047. Epub 2009 Feb 4.
9
Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.单独使用人纯化抗凝血酶或在低分子量肝素或普通肝素存在的情况下,对与人类血凝块相关的凝血酶生成进行药理学调节。
Blood Coagul Fibrinolysis. 2000 Jan;11(1):51-9.
10
A comparison of pentosan polysulphate (SP54) and heparin. I: Mechanism of action on blood coagulation.戊聚糖多硫酸酯(SP54)与肝素的比较。I:对血液凝固的作用机制
Thromb Haemost. 1982 Apr 30;47(2):104-8.

引用本文的文献

1
New anticoagulants for the prevention and treatment of venous thromboembolism.用于预防和治疗静脉血栓栓塞症的新型抗凝剂。
Vasc Health Risk Manag. 2005;1(1):41-53. doi: 10.2147/vhrm.1.1.41.58936.